GlassScriptPhysician profile
Dmitriy I Pales
NPI 1548282700
$5,101.69
in general payments reported to CMS, 2019-2025
52 companies · $751 in 2025
The $751 reported for 2025 was more than what 93% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $688 · 2021: $995 · 2022: $895 · 2023: $785 · 2024: $681 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,201 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,201.11 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $648.42 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $605.02 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $513.24 | 2020-2025 | Mounjaro, Zepbound, Kisunla |
| Abbvie INC. | $479.93 | 2019-2025 | |
| Novo Nordisk INC | $317.10 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $286.94 | 2021-2024 | Repatha, Otezla |
| Pfizer INC. | $256.47 | 2019-2025 | |
| Exact Sciences Corporation | $189.40 | 2023-2025 | Cologuard Collection Kit |
| Genzyme Corporation | $187.59 | 2019-2023 | |
| Glaxosmithkline, LLC. | $104.04 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Aimmune Therapeutics, INC. | $101.12 | 2024-2025 | Zenpep |
| Ucb, INC. | $94.74 | 2020-2024 | Nayzilam |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.98 | 2021-2023 | Tradjenta, Synjardy, Glyxambi |
| Seqirus USA INC | $73.36 | 2021-2025 | Flucelvax, Fluad, Fluad Quadrivalent |
| Merck Sharp & Dohme LLC | $73.06 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitriy Pales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.